Tokio Marine Asset Management Co. Ltd. Raises Stake in Agilent Technologies, Inc. (NYSE:A)

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 2.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 8,058 shares of the medical research company’s stock after acquiring an additional 168 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Agilent Technologies were worth $1,196,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Western Pacific Wealth Management LP increased its position in Agilent Technologies by 18.9% during the first quarter. Western Pacific Wealth Management LP now owns 440 shares of the medical research company’s stock worth $64,000 after purchasing an additional 70 shares during the last quarter. Menard Financial Group LLC raised its stake in shares of Agilent Technologies by 1.6% during the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock valued at $628,000 after purchasing an additional 77 shares in the last quarter. McAdam LLC grew its holdings in Agilent Technologies by 3.1% during the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares during the period. Global Retirement Partners LLC increased its stake in Agilent Technologies by 3.2% in the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares in the last quarter. Finally, Rovin Capital UT ADV increased its holdings in shares of Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares during the period.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This represents a 7.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. The trade was a 19.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,995 shares of company stock valued at $1,739,510.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group boosted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Evercore ISI boosted their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Citigroup raised their price objective on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Barclays upped their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research note on Tuesday, October 15th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Price Performance

Shares of NYSE A opened at $127.07 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The company has a 50 day moving average of $138.93 and a 200 day moving average of $138.08. Agilent Technologies, Inc. has a twelve month low of $112.06 and a twelve month high of $155.35. The firm has a market cap of $36.51 billion, a P/E ratio of 26.36, a PEG ratio of 5.91 and a beta of 1.07.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the firm posted $1.43 EPS. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, research analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were given a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is currently 19.50%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.